Skip to content

Govt Tells SC It Will Cap Cancer Drug Trade Margins

By News Analysis India · · 1 min read

In a fresh affidavit before the Supreme Court, the Central government has said it will restrict trade margins on certain non-scheduled cancer drugs to 30 percent of their maximum retail price. The move is aimed at reducing the high costs that cancer patients face for treatment.

The government has formed a specialised expert committee to prepare a list of cancer medicines to which this cap may apply. The Health Ministry constituted the committee on October 9, 2026. It is headed by the Director General of Health Services, and has been directed to deliver its report within 10 to 15 days.

Once the report is available, the National Pharmaceutical Pricing Authority, or NPPA, will consider the matter and issue required instructions, the affidavit said. The government argues that this process will stop businesses from earning unwarranted profits from essential medicines.

Officials expect the measure to bring the MRP of affected cancer drugs down by about 20 to 70 percent. The government estimates that patients could save nearly 2,500 crore rupees every year as a result.

The Centre also reiterated that it has previously taken action to control the prices of various drugs and medical products. It further admitted before the court that it is aware of the problem of excessive charges for medicines and medical items in hospitals, and said it is exploring ways to address the issue.

The affidavit pointed out that Indian companies produce many medicines at affordable rates, but patients still often end up paying large sums. Hospitals hold far greater bargaining power than patients, who generally lack information about correct drug prices and cheaper options. Certain hospitals have been found charging as much as 700 percent above the actual cost of cancer drugs.